Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | ELOVL1 | Q9BW60 | 10/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL1356496 | 0.71 | SIGMAR1 (0.63) | SIGMAR1SMN1; SMN2L3MBTL1 | |
| SCHEMBL1357638 | 0.69 | SIGMAR1 (0.71) | SIGMAR1HTR2BL3MBTL1 | |
| SCHEMBL1356203 | 0.63 | SIGMAR1 (0.38) | SIGMAR1SMN1; SMN2TSHR | |
| SCHEMBL1356487 | 0.62 | SIGMAR1 (0.57) | SIGMAR1HTR2BSMN1; SMN2TSHR | |
| SCHEMBL1357556 | 0.61 | SIGMAR1 (0.80) | SIGMAR1TSHRL3MBTL1 | |
| SCHEMBL1356701 | 0.61 | SIGMAR1 (0.61) | SIGMAR1SMN1; SMN2TSHRHTT | |
| SCHEMBL10417212 | 0.60 | ABCB11 (0.74) | MAPTSMN1; SMN2HTTMAPK10 | |
| SCHEMBL4745958 | 0.60 | AKR1C3 (0.69) | SIGMAR1AKR1C3MAPTSMN1; SMN2TSHR | |
| SCHEMBL20485457 | 0.60 | ELOVL1 (0.53) | ELOVL1MAPTTSHRHTTHSD17B10 | |
| SCHEMBL20485326 | 0.60 | ELOVL1 (0.68) | ELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994008-B1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2016-08-10 | — | — | EP | disclosed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | disclosed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885AKR1C3 1291/4885ELOVL1 3352/4885 |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885AKR1C3 1291/4885ELOVL1 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.